Why did UBS cut Braze's price target so dramatically?

UBS reduced their target from $43 to $28 (35% cut) while maintaining a Buy rating, suggesting they see structural headwinds in customer acquisition costs or competitive positioning that aren't reflected in recent earnings beats.

How does UBS's target compare to other analysts?

UBS's $28 target sits $7.10 below the Street consensus of $35.10, creating the largest gap among major banks covering Braze and signaling potential fundamental disagreements about the company's trajectory.

What metrics should investors watch to validate UBS's concerns?

Key indicators include net revenue retention rates, customer acquisition cost trends, and revenue per customer metrics. Any deterioration in these areas would support UBS's more conservative valuation stance.

Is this target cut typical for growth stocks?

Target cuts of 35% while maintaining Buy ratings are unusual and often precede broader analyst downgrades as fundamental concerns spread across the coverage universe.

What's the investment implication of this analyst disconnect?

The large gap between UBS and consensus suggests either UBS is early in recognizing problems or other analysts will soon revise targets downward, creating potential downside risk even if Braze executes well operationally.

BRZEMarch 27, 2026

By Basis Report Editorial · Updated April 1, 2026

UPDATE March 31: Braze stock surged 19.9% on Q4 2026 earnings after revenue beat consensus estimates, invalidating the original article's core framing. The piece cited UBS's cut to $35 as a bellwether for bearish sentiment — UBS has since slashed its target further to $28 (from $43), and Oppenheimer trimmed to $30 from $40 even while holding an Outperform rating. At least five analysts reset price targets lower post-print, collapsing the Street consensus well below levels referenced here. The key offset: Braze guided toward its first profitable fiscal year, a milestone management has deferred repeatedly. That single data point is what drove the gap-up and explains why near-term sentiment has reversed sharply despite the across-the-board target cuts. Bears own the 12-month valuation argument; bulls own the momentum trade and a credible profitability inflection. Watch Q1 2027 revenue and operating margin guidance when Braze reports next quarter — specifically whether non-GAAP operating income turns positive YoY. That print will determine whether the profitability narrative holds or reverts to prior form.

```html

Braze Price Target Slashed 35% by UBS While Street Stays Bullish at $35

NEW YORK, March 27 —

UBS cut Braze's price target 35% — from $43 to $28 — while holding its Buy rating. The Street consensus sits at $35.10, leaving a $7.10 gap between UBS and the rest of the analyst pack. That spread is unusually wide. Aggressive target cuts paired with maintained Buy ratings have historically preceded broader downgrades as revenue growth or margins deteriorate.

What the Street Believes

Analysts peg consensus at $35.10, implying 50.6% upside from Braze's current $23.31 price. They point to AI product expansion and enterprise customer additions as the primary growth drivers. Braze's Q4 results support the bull case. The company reported $0.07 per share against a $0.04621 consensus estimate, a 43.3% beat.

The Street expects margin expansion from Braze's 67.1% gross margin base, with the path to profitability widening the valuation multiple. Braze generated $178mn in trailing free cash flow on $738mn in revenue. Most analysts rate the company a Buy and see no cracks in the growth story.

What the Data Shows

The Street's models call for steady revenue growth. UBS, meanwhile, cut its target by $15 per share in a single revision. A $15 move is not a rounding error. It is a full recalibration — reflecting either rising customer acquisition costs, faster competitive share loss, or both.

"UBS Adjusts Braze Price Target to $28 From $43, Maintains Buy Rating"

The timing sharpens the concern. UBS made the revision after Braze reported solid Q4 numbers, not before. The cut is not a reaction to a miss — it reflects a reassessment of the forward outlook. The $28 target sits just 20% above the current price. For a growth stock, that is a thin cushion.

Why This Changes the Calculus

If UBS is right, Braze's valuation faces a structural reset that the rest of the Street has not yet reflected. The customer engagement platform market has grown crowded. SendGrid, Twilio, and AI-native competitors are taking share. UBS may be the first to model declining revenue per customer or rising churn among enterprise accounts.

Net revenue retention is the first metric to watch. Any drop below the high-90s percentage range would validate UBS's conservative stance and likely pull other analyst targets lower. Customer acquisition cost trends are the second signal. If CAC payback periods stretch beyond historical norms, the growth-at-reasonable-price case collapses.

The Counterargument

Bulls argue UBS is too pessimistic. Braze's AI product expansion and enterprise customer additions should lift customer lifetime values. The company's shift toward profitability and improving free cash flow generation show the cost structure is tightening. Recent partnership announcements and product launches suggest Braze is holding ground against competitors. The Q3 earnings surprise of 399.1% is difficult to reconcile with UBS's downward revision.

Verdict

UBS's 35% target cut sets up a bear case the rest of the Street has not yet adopted. A major bank that lowers its target by $15 per share while holding a Buy rating is typically ahead of a broader analyst reset. The $7.10 gap between UBS's $28 and the Street consensus narrows to two possibilities: UBS is wrong, or other analysts follow with their own cuts — the same pattern that emerges when revenue beats obscure weakening forward guidance.